The unified proposal for classification of human respiratory syncytial virus below the subgroup level

Author:

Goya StephanieORCID,Ruis Christopher,Neher Richard A.ORCID,Meijer AdamORCID,Aziz Ammar,Hinrichs Angie S.ORCID,von Gottberg AnneORCID,Roemer CorneliusORCID,Amoako Daniel G.ORCID,Acuña DoloresORCID,McBroome JakobORCID,Otieno James R.ORCID,Bhiman Jinal N.ORCID,Everatt JosieORCID,Muñoz-Escalante Juan C.ORCID,Ramaekers KaatORCID,Duggan Kate,Presser Lance D.ORCID,Urbanska Laura,Venter MarietjieORCID,Wolter NicoleORCID,Peret Teresa C. T.ORCID,Salimi VahidORCID,Potdar VarshaORCID,Borges VítorORCID,Viegas MarianaORCID

Abstract

AbstractA globally implemented unified classification for human respiratory syncytial virus (HRSV) below the subgroup level remains elusive. Here, we formulate the global consensus of HRSV classification based on the challenges and limitations of our previous proposals and the future of genomic surveillance. From a high-quality dataset of 1,480 HRSV-A and 1,385 HRSV-B genomes submitted to NCBI and GISAID up to March 2023, we categorized HRSV-A/B sequences into lineages based on phylogenetic clades and amino acid markers. We defined 24 lineages within HRSV-A and 16 within HRSV-B, providing guidelines for prospective lineages definition. Our classification demonstrated robustness in its applicability to both complete and partial genomes. In addition, it allowed the observation of notable lineage replacements and the identification of lineages exclusively detected since the COVID-19 pandemic. We envision that this unified HRSV classification proposal will strengthen and facilitate HRSV molecular epidemiology on a global scale.

Publisher

Cold Spring Harbor Laboratory

Reference50 articles.

1. GSK. European Commission authorises GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults | GSK. 2023. Available from: https://www.gsk.com/en-gb/media/press-releases/european-commission-authorises-gsk-s-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/

2. Pfizer. U.S. FDA Approves ABRYSVO, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age. 2023. Available from: https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-abrysvotm-pfizers-vaccine-prevention-0

3. AstraZeneca. Nirsevimab unanimously recommended by FDA Advisory Committee for the prevention of RSV lower respiratory tract disease in infants. 2023. Available from: https://www.astrazeneca.com/media-centre/press-releases/2023/nirsevimab-recommended-for-infant-rsv-protection.html

4. Antigenic Characterization of Respiratory Syncytial Virus Strains with Monoclonal Antibodies

5. Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3